Phase Ib trial of EPI 589 in healthy subjects

Trial Profile

Phase Ib trial of EPI 589 in healthy subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2014

At a glance

  • Drugs EPI 589 (Primary)
  • Indications Neurodegenerative disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Feb 2014 New trial record
    • 31 Jan 2014 EPI-589 is currently in phase 1B, according to an Edison Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top